This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Conducting Effective Global Anti–Money Laundering Investigations in a Complex Regulatory Environment

Abstract

Global anti–money laundering (AML) investigations present complex operational and regulatory challenges driven by cross-border transactions, fragmented data sources, varying legal regimes, data protection and privacy requirements, and cultural barriers to information sharing. These challenges are further compounded by jurisdictional limitations that may restrict direct cross-border inquiries and require reliance on regulator-to-regulator coordination. Effective global investigations therefore demand a structured, risk-based approach that balances investigative rigor with legal and regulatory permissibility across jurisdictions. This paper outlines leading practices for conducting global AML investigations, including the establishment of clear governance and escalation protocols, preservation of evidence, identification of beneficial ownership, and mapping of transactional flows across multiple jurisdictions. It emphasizes alignment with international standards such as the Financial Action Task Force (FATF) Recommendations and guidance from the U.S. Department of Justice, highlighting the importance of investigative independence, comprehensive documentation, and proportionate remediation. Particular attention is given to the practical challenges of obtaining information in jurisdictions subject to data protection frameworks and regulatory gatekeeping, underscoring the need for early legal engagement and structured escalation pathways. The analysis also considers the role of cross-border information-sharing mechanisms, including supervisory cooperation and mutual legal assistance frameworks, when direct investigative access to information is constrained. Ultimately, a well-executed global AML investigation is positioned not merely as a reactive response to potential misconduct, but as a strategic capability that strengthens organizational resilience, reinforces ethical culture, and mitigates legal, financial, and reputational risk in an increasingly interconnected regulatory environment.

PLS LogoCopyright & permissions

Authors

Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA

M. Fabiana Lacerca-Allen is a senior compliance and legal executive with over 30 years of experience leading global compliance, legal, and governance programs across the pharmaceutical, biotechnology, and technology sectors. She currently serves as Chief Compliance Officer for Cipla USA and has held senior leadership roles at Aimmune Therapeutics, Elan Pharmaceuticals, Mylan, Bristol-Myers Squibb, Microsoft, Merck, and AT&T. She brings deep expertise in risk-based compliance program design aligned with DOJ and OIG expectations, including third-party risk management, global investigations, data integrity, ethical culture transformation, and crisis preparedness. She regularly advises boards and executive leadership teams on international operations and enterprise governance. Fabiana serves as a Board Director and Audit Committee Member of Shield Therapeutics and holds a risk and governance advisory position with the International Federation of Red Cross and Red Crescent Societies (IFRC). She is also Adjunct Professor at Fordham University School of Law, teaching compliance, ethics, and governance. She is author of Crisis Capable and a frequent international speaker. She previously served as Chair of the Bay Area Ethics & Compliance Association and Co-Chair for CBI (Advanstar). She holds a JD and LLM and conducted academic research in international environmental law through the Gioja Research Institute.

Portrait image of Kwanza Burney
Kwanza Burney
Compliance & Risk Professional | M.S.L. Candidate (Fordham Law), Fordham University School of Law, US

Kwanza Burney is a compliance and operations professional with extensive experience in regulated financial services environments. Her background includes leading quality assurance, compliance testing, and risk assessment initiatives, with a focus on strengthening governance frameworks and driving process improvements. She has held leadership roles in global operations, managing cross-functional teams and supporting regulatory readiness across complex organizations. Kwanza is currently pursuing a Master of Studies in Law (M.S.L.) in Corporate Compliance at Fordham University School of Law, further deepening her expertise in regulatory and compliance strategy.

Companies

Cipla logo

Cipla

Cipla Limited is a leading Indian multinational pharmaceutical company, founded in 1935, focused on developing high-quality, affordable medicines across various therapeutic areas, including respiratory, cardiovascular, and HIV/AIDS. With 46 global manufacturing sites, it produces 1,500+ products and operates in 80+ countries.

Fordham University School of Law

Fordham University School of Law is a leading institution in legal education, with a strong focus on corporate compliance, ethics, and regulatory practice.

Related Papers

“Crisis-Capable Compliance: The CCO at the Crossroads of AI, Ethics, and Leadership”
The role of the Chief Compliance Officer is undergoing a fundamental transformation in the era of artificial intelligence. No longer confined to oversight and enforcement, the CCO is emerging as...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Dolores Guzman
Dolores Guzman
Legal & Compliance Director , Apex America , UK
Anti Money Laundering Risk in Private Credit: Governance Gaps in a Rapidly Expanding Market
Anti–money laundering (AML) risk is structurally amplified in cross-border third-party relationships, particularly within the rapidly expanding private credit sector. Industry estimates place the global private credit market at approximately $3...Read more
Portrait image of Aaron Lee
Aaron Lee
Vice President and Chief Compliance Officer, Fred Alger & Company, LLC, USA
Portrait image of Sarah Rich
Sarah Rich
Compliance Officer, Manhattan-Based Global Asset Manager and an ACAMS Certified Anti-Money Laundering Specialist, USA
Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Valentina Lacerca-Allen
Valentina Lacerca-Allen
Title Marketing/ Communication Specialist, Ethiprax LLC., USA
March-In Rights at a Crossroad: What Biopharma Needs To Know Under Trump Administration
Few pieces of legislation have shaped the modern innovation landscape as profoundly as the Bayh-Dole Act of 1980. By allowing universities, small businesses, and non-profit organizations to retain ownership...Read more
Portrait image of Joanna Brougher
Joanna Brougher
Owner & Principal, BioPharma Law Group PLLC, USA
Portrait image of Bhavya Bhardwaj
Bhavya Bhardwaj
Student, University of Pennsylvania, USA